Condition (MeSH)
Rhinorrhea
ClinicalTrials.gov lists 30 trials for Rhinorrhea or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
19 of the 30 trials are tagged with Rhinorrhea itself; the rest are tagged with a narrower condition beneath it.
When did Rhinorrhea trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 1 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 35 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 13 months across 22 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Rhinorrhea trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 3 | 6 |
| Phase 4 | 4 |
| Not applicable | 12 |
| Observational | 1 |
How many Rhinorrhea trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Active, not recruiting | 2 |
| Completed | 21 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Rhinorrhea trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AstraZeneca | 3 |
| Faes Farma, S.A. | 3 |
| UCB Pharma | 2 |
| Altamira Medica Ltd. | 1 |
| Kuros Biosurgery AG | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Rhinorrhea? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Bilastine | 3 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Budesonide EC | 3 |
| Levocetirizine only | 3 |
| Desloratadin | 2 |
| Topical Lidocaine | 1 |
| Wintergreen Throat Spray and Aspirin Tablet | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Rhinorrhea? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Evaluation of the Live-Attenuated Intranasal Respiratory Syncytial Virus (RSV) Vaccine RSV/6120/ΔNS2/1030s in RSV-Seronegative Young Children. | The Journal of infectious diseases | 2024 | No |
| Temperature-controlled radiofrequency neurolysis for treatment of chronic rhinitis: 12-month outcomes after treatment in a randomized controlled trial. | International forum of allergy & rhinology | 2023 | No |
| Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. | American journal of respiratory and critical care medicine | 2021 | No |
| OnabotulinumtoxinA injection towards the SPG for treating symptoms of refractory chronic rhinosinusitis with nasal polyposis: a pilot study. | Acta oto-laryngologica | 2021 | No |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.